STOCKHOLDERS’ EQUITY (Tables)
|
9 Months Ended |
Mar. 31, 2022 |
|---|
| Equity [Abstract] |
|
| SCHEDULE OF STOCK WARRANT ACTIVITY |
Warrant
detail for the nine months ended March 31, 2022 is reflected below:
SCHEDULE OF STOCK WARRANT ACTIVITY
| |
|
Number of Warrants |
|
|
Weighted Average Exercise Price Per Warrant |
|
|
Weighted Average Remaining Contract Term (# years) |
|
| Warrants outstanding and exercisable at June 30, 2021 |
|
|
214,883 |
|
|
$ |
4.49 |
|
|
|
|
|
| Warrants issued |
|
|
1,071,430 |
|
|
$ |
7.00 |
|
|
|
|
|
| Warrants outstanding and exercisable at March 31, 2022 |
|
|
1,286,313 |
|
|
$ |
6.58 |
|
|
|
4.11 |
|
Warrant
detail for the nine months ended March 31, 2021 is reflected below:
| |
|
Number of Warrants |
|
|
Weighted Average Exercise Price Per Warrant |
|
|
Weighted Average Remaining Contract Term (# years)
|
|
| Warrants outstanding and exercisable at June 30, 2020 |
|
|
83,205 |
|
|
$ |
4.00 |
|
|
|
|
|
| Warrants issued |
|
|
185,955 |
|
|
$ |
4.80 |
|
|
|
|
|
| Warrants exercised |
|
|
(32,977 |
) |
|
$ |
4.80 |
|
|
|
|
|
| Warrants forfeited |
|
|
(11,700 |
) |
|
$ |
4.80 |
|
|
|
|
|
| Warrants outstanding at March 31, 2021 |
|
|
224,483 |
|
|
$ |
4.50 |
|
|
|
3.22 |
|
|
| SCHEDULE OF STOCK OPTIONS ACTIVITY |
Activity
in the Company’s stock options during the nine months ended March 31, 2022 and related balances outstanding as of that date are
reflected below:
SCHEDULE OF STOCK OPTIONS ACTIVITY
| |
|
Number of Shares |
|
|
Weighted Average Exercise Price |
|
|
Weighted Average Remaining Contract Term (# years)
|
|
| Outstanding at June 30, 2021 |
|
|
531,205 |
|
|
$ |
11.02 |
|
|
|
|
|
| Granted |
|
|
- |
|
|
$ |
- |
|
|
|
|
|
| Exercised |
|
|
(3,400 |
) |
|
$ |
4.65 |
|
|
|
|
|
| Forfeited and cancelled |
|
|
(15,612 |
) |
|
$ |
14.28 |
|
|
|
|
|
| Outstanding and exercisable at March 31, 2022 |
|
|
512,193 |
|
|
$ |
10.97 |
|
|
|
5.91 |
|
Activity
in the Company’s stock options during the nine months ended March 31, 2021 and related balances outstanding as of that date are
reflected below:
| |
|
Number of Shares |
|
|
Weighted Average Exercise Price |
|
|
Weighted Average Remaining Contract Term (# years)
|
|
| Outstanding at June 30, 2020 |
|
|
579,584 |
|
|
$ |
11.00 |
|
|
|
|
|
| Granted |
|
|
- |
|
|
$ |
- |
|
|
|
|
|
| Exercised |
|
|
(15,812 |
) |
|
$ |
5.77 |
|
|
|
|
|
| Forfeited and cancelled |
|
|
(18,932 |
) |
|
$ |
12.45 |
|
|
|
|
|
| Outstanding at March 31, 2021 |
|
|
544,840 |
|
|
$ |
11.10 |
|
|
|
6.81 |
|
| Exercisable at March 31, 2021 |
|
|
490,493 |
|
|
$ |
10.91 |
|
|
|
6.67 |
|
|
| SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY |
Activity
in RSUs during the nine months ended March 31, 2022 and related balances outstanding as of that date are reflected below:
SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY
| |
|
Number of Shares |
|
|
Weighted Average Grant date Fair Value |
|
|
Weighted Average Remaining Contract Term (# years)
|
|
| Outstanding at June 30, 2021 |
|
|
131,652 |
|
|
$ |
9.25 |
|
|
|
|
|
| Granted |
|
|
179,614 |
|
|
$ |
5.75 |
|
|
|
|
|
| Settled |
|
|
(4.578 |
) |
|
$ |
11.56 |
|
|
|
|
|
| Forfeited and cancelled |
|
|
(35,542 |
) |
|
$ |
6.95 |
|
|
|
|
|
| Outstanding at March 31, 2022 |
|
|
271,146 |
|
|
$ |
7.19 |
|
|
|
2.34 |
|
Activity
in RSUs during the nine months ended March 31, 2021 and related balances outstanding as of that date are reflected below:
| |
|
Number of Shares |
|
|
Weighted Average Grant date Fair Value |
|
|
Weighted Average Remaining Contract Term (# years)
|
|
| Outstanding at June 30, 2020 |
|
|
- |
|
|
$ |
- |
|
|
|
|
|
| Granted |
|
|
134,865 |
|
|
$ |
8.88 |
|
|
|
|
|
| Forfeited and cancelled |
|
|
(6,542 |
) |
|
$ |
8.88 |
|
|
|
|
|
| Outstanding at March 31, 2021 |
|
|
128,323 |
|
|
$ |
8.88 |
|
|
|
2.91 |
|
|
| SCHEDULE OF STOCK-BASED COMPENSATION EXPENSES |
The
following table summarizes stock-based compensation expense for employee and non-employee stock option and RSU grants:
SCHEDULE OF STOCK-BASED COMPENSATION EXPENSES
| |
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
| |
|
Three Months Ended
March 31, |
|
|
Nine Months Ended
March 31, |
|
| |
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
| Research and development |
|
$ |
32,000 |
|
|
$ |
48,000 |
|
|
$ |
122,000 |
|
|
$ |
146,000 |
|
| Selling and administrative |
|
|
120,000 |
|
|
|
180,000 |
|
|
|
479,000 |
|
|
|
504,000 |
|
| Total stock-based compensation expense |
|
$ |
152,000 |
|
|
$ |
228,000 |
|
|
$ |
601,000 |
|
|
$ |
650,000 |
|
|